

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Kangji Medical Holdings Limited**

**康基医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9997)**

## **CHANGE OF DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Kangji Medical Holdings Limited (the “**Company**”), and together with its subsidiaries, the “**Group**”) hereby announces that with effect from April 28, 2022:

- (i) Mr. CHEN Gang (“**Mr. Chen**”) ceased to be a non-executive Director due to other work commitments; and
- (ii) Mr. YIN Zixin (“**Mr. Yin**”), one of the joint company secretaries of the Company, has been appointed as an executive Director.

Mr. Chen has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation or termination of appointment that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The biographical details of Mr. Yin and other information to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) are as follows:

Mr. Yin, aged 36, was appointed as our vice general manager and one of our joint company secretaries on March 7, 2020. Mr. Yin joined the Group in September 2016 as a general manager assistant and has acted as the secretary to the board since November 8, 2016 at Hangzhou Kangji Medical Instrument Ltd. (杭州康基醫療器械有限公司) (“**Hangzhou Kangji**”), an indirect wholly-owned subsidiary of the Company. Mr. Yin has been a director at Hangzhou Kangji since August 2020 and a director at Hangzhou Weijing Medical Robot Co., Ltd. (杭州唯精醫療機器人有限公司) (“**Hangzhou Weijing**”) since February 2022. Hangzhou Weijing will be held as to 35% by Kangji Medical (Hong Kong) Limited upon completion of the investment as disclosed in the announcement of the Company dated January 18, 2022. Mr. Yin is mainly responsible for investor relationships, investment and corporate governance matters of the Group.

Before joining the Group, from July 2008 to October 2010, Mr. Yin served as a department manager at Hangzhou Yingce Enterprise Management and Consultation Co., Ltd.\* (杭州英策企業管理諮詢有限公司), where he was primarily responsible for product and business development. From November 2010 to August 2016, Mr. Yin worked as an investment manager and assistant to the chairman of the board at Wanma United Holding Group Co., Ltd.\* (萬馬聯合控股集團有限公司), where he was primarily responsible for investments, and mergers and acquisitions.

Mr. Yin obtained his bachelor's degree in economics and management from Zhejiang University of Finance & Economics (浙江財經大學) in the PRC in June 2008.

Mr. Yin has entered into a service contract with the Company for his appointment as an executive Director for a term of three years commencing from April 28, 2022. The appointment is subject to retirement by rotation and re-election at the general meetings in accordance with the articles of association of the Company, including being re-elected in the upcoming annual general meeting of the Company. Pursuant to the service contract entered into between Mr. Yin and the Company, Mr. Yin will not receive any Director's salary or fee from the Company during his term of office but he is entitled to an annual emolument of RMB400,000 and discretionary bonus as determined by the Board upon recommendation from the remuneration committee of the Company with reference to the prevailing market conditions and his managerial position as the vice general manager. As at the date of this announcement, Mr. Yin is interested in the restricted share units granted to him in accordance with the Company's restricted share unit plan in respect of 4,125,000 underlying ordinary shares of the Company.

Save as disclosed, as at the date of this announcement, Mr. Yin (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other positions with the Company or other members of the Group; (iii) did not hold any directorship in the last three years before his appointment date in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company.

Mr. Yin confirms that, in relation to his appointment as an executive Director, there is no other information which is discloseable under Rule 13.51(2) of the Listing Rules, and the Company is not aware of any other matters in relation to the appointment that need to be brought to the attention of Shareholders.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Chen for his valuable contributions to the Company during his tenure of service and extend its warm welcome to Mr. Yin on his new appointment.

By order of the Board  
**Kangji Medical Holdings Limited**  
**ZHONG Ming**  
*Chairman*

Hangzhou, PRC, April 28, 2022

*As at the date of this announcement, the Board comprises Mr. ZHONG Ming, Ms. SHENTU Yinguang, Ms. Frances Fang CHOVANEC and Mr. Yin Zixin as executive Directors; Ms. CAI Li as non-executive Director; and Mr. JIANG Feng, Mr. GUO Jian and Mr. CHEN Weibo as independent non-executive Directors.*

\* *For identification purpose only*